SideroxylinCAS# 3122-87-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 3122-87-0 | SDF | Download SDF |
PubChem ID | 3083788 | Appearance | Yellow powder |
Formula | C18H16O5 | M.Wt | 312.3 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-6,8-dimethylchromen-4-one | ||
SMILES | CC1=C(C2=C(C(=C1OC)C)OC(=CC2=O)C3=CC=C(C=C3)O)O | ||
Standard InChIKey | QJSQOGJCHBXLAH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H16O5/c1-9-16(21)15-13(20)8-14(11-4-6-12(19)7-5-11)23-18(15)10(2)17(9)22-3/h4-8,19,21H,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Sideroxylin can synergistically enhance the antimicrobial activity of the alkaloid berberine (also a constituent of H. canadensis) against Staphylococcus aureus by inhibition of the NorA multidrug resistance pump. |
Targets | Antifection |
Sideroxylin Dilution Calculator
Sideroxylin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.202 mL | 16.0102 mL | 32.0205 mL | 64.041 mL | 80.0512 mL |
5 mM | 0.6404 mL | 3.202 mL | 6.4041 mL | 12.8082 mL | 16.0102 mL |
10 mM | 0.3202 mL | 1.601 mL | 3.202 mL | 6.4041 mL | 8.0051 mL |
50 mM | 0.064 mL | 0.3202 mL | 0.6404 mL | 1.2808 mL | 1.601 mL |
100 mM | 0.032 mL | 0.1601 mL | 0.3202 mL | 0.6404 mL | 0.8005 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- H-D-Ser-OH
Catalog No.:BCC2676
CAS No.:312-84-5
- Methylionene
Catalog No.:BCN7120
CAS No.:31197-54-3
- Sudan II
Catalog No.:BCN8383
CAS No.:3118-97-6
- D-Xylose
Catalog No.:BCC8320
CAS No.:31178-70-8
- SYM 2081
Catalog No.:BCC6840
CAS No.:31137-74-3
- RFRP 3 (human)
Catalog No.:BCC6261
CAS No.:311309-27-0
- 3-Methyl-4-nitrobenzoic acid
Catalog No.:BCN2261
CAS No.:3113-71-1
- Taxifolin 3'-O-glucoside
Catalog No.:BCN6808
CAS No.:31106-05-5
- Benzoquinonium dibromide
Catalog No.:BCC6641
CAS No.:311-09-1
- 5,7,3'-Trihydroxy-6,4',5'-trimethoxyflavanone
Catalog No.:BCN1461
CAS No.:310888-07-4
- PRT 4165
Catalog No.:BCC6354
CAS No.:31083-55-3
- Decylic acid vanillylamide
Catalog No.:BCN7836
CAS No.:31078-36-1
- Eucalyptin
Catalog No.:BCN5227
CAS No.:3122-88-1
- Cimigenol-3-one
Catalog No.:BCN7430
CAS No.:31222-32-9
- IQ 3
Catalog No.:BCC8093
CAS No.:312538-03-7
- Tetrahydrocannabivarin
Catalog No.:BCN6935
CAS No.:31262-37-0
- SKI II
Catalog No.:BCC5029
CAS No.:312636-16-1
- THIQ
Catalog No.:BCC7539
CAS No.:312637-48-2
- gamma-Mangostin
Catalog No.:BCN5228
CAS No.:31271-07-5
- Indacaterol
Catalog No.:BCC1650
CAS No.:312753-06-3
- Hygromycin B
Catalog No.:BCC1204
CAS No.:31282-04-9
- Raucaffricine
Catalog No.:BCN4653
CAS No.:31282-07-2
- TCS JNK 5a
Catalog No.:BCC5148
CAS No.:312917-14-9
- LDN-27219
Catalog No.:BCC6236
CAS No.:312946-37-5
An Isoflavone from Leiophyllum buxifolium and Its Antiproliferative Effect.[Pubmed:26086179]
J Nat Prod. 2015 Jul 24;78(7):1748-51.
A new C-methylisoflavone, isoSideroxylin (1), and a known C-methylflavone, Sideroxylin (2), were isolated from the EtOAc extract of the leaves of Leiophyllum buxifolium. The two compounds were evaluated with the sulforhodamine B assay for their antiproliferative effects against ER(-) MDA-MB-231 and ER(+) MCF-7 breast cancer cell lines and the NIH3T3 mouse fibroblast cell line. IsoSideroxylin (1) displayed a selective antiproliferative effect against MDA-MB-231 cells.
Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis).[Pubmed:21661731]
J Nat Prod. 2011 Jul 22;74(7):1621-9.
It is often argued that the efficacy of herbal medicines is a result of the combined action of multiple constituents that work synergistically or additively. Determining the bioactive constituents in these mixtures poses a significant challenge. We have developed an approach to address this challenge, synergy-directed fractionation, which combines comprehensive mass spectrometry profiling with synergy assays and natural products isolation. The applicability of synergy-directed fractionation was demonstrated using the botanical medicine goldenseal (Hydrastis canadensis) as a case study. Three synergists from goldenseal were identified, Sideroxylin, 8-desmethyl-Sideroxylin, and 6-desmethyl-Sideroxylin. These flavonoids synergistically enhance the antimicrobial activity of the alkaloid berberine (also a constituent of H. canadensis) against Staphylococcus aureus by inhibition of the NorA multidrug resistance pump. The flavonoids possess no inherent antimicrobial activity against S. aureus; therefore, they could have been missed using traditional bioactivity-directed fractionation. The flavonoid synergists are present at higher concentration in extracts from H. canadensis leaves, while the antimicrobial alkaloid berberine is present at higher levels in H. canadensis roots. Thus, it may be possible to produce an extract with optimal activity against S. aureus using a combination of goldenseal roots and leaves.
C-methylflavonoids isolated from Callistemon lanceolatus protect PC12 cells against Abeta-induced toxicity.[Pubmed:20101562]
Planta Med. 2010 Jun;76(9):863-8.
Increased beta-amyloid (Abeta) production and its aggregation to the oligomeric state is considered to be a major cause of Alzheimer's disease (AD). Therefore, reducing Abeta-induced neurotoxicity could provide a suitable means of prevention or intervention in the disease course of AD. The neuroprotective effects of isolates from Callistemon lanceolatus DC. (Myrtaceae) against Abeta were evaluated using PC12 cells. To evaluate the effects of Abeta on apoptotic cell death and the effects of Bcl-2 family proteins and caspase-3, TUNEL assays and Western blotting were performed, respectively. Substantial fractionation and purification of the EtOAc-soluble extract of the aerial parts of C. lanceolatus afforded six flavonoids, 4',5-dihydroxy-6,8-dimethyl-7-methoxyflavanone (1), eucalyptin (2), 8-demethyleucalyptin (3), Sideroxylin (4), syzalterin (5), and quercetin (6). Compounds 1, 5, and 6 were found to protect PC12 cells effectively against Abeta-induced toxicity. In particular, compound 1 showed the most promising neuroprotective effect with an ED (50) value of 6.7 microM in terms of decreasing Abeta-induced apoptotic cell death, and this was accompanied by a decrease in caspase-3 activation and an increase in Bcl-2/Bax ratio. These results suggest that compound 1 could be developed as a candidate anti-AD agent due to its attenuation of Abeta-induced apoptotic cell death.